top_image
SCB-808 (Etanercept Biosimilar): Rheumatology

SCB-808 is an etanercept biosimilar being developed as a ready-for-injection prefilled syringe formulation. All currently available etanercept biosimilars in China are approved as freeze-dried powder formulations only.
.
Clover has successfully completed Phase I clinical testing; a Phase III clinical trial began in 2019.